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e-mail address: AGLee@HoustonMethodist.org (A.G. Lee).Sumayya J. Almarzouqi a, Michael L. Morgan a, Andrew G. Lee a,b,c,d,e,f,g,h,⇑AbstractIdiopathic Intracranial Hypertension (IIH) is a disorder of increased intracranial pressure without any identifiable etiology. It is
defined by elevated intracranial pressure (ICP) with normal neuroimaging and normal cerebrospinal fluid (CSF) contents. IIH
typically affects young obese women and produces symptoms and signs related to high ICP. Headache and blurred vision are
the most common symptoms, and papilledema is the major clinical sign. In this review we examine the epidemiology and
demographic features of IIH in Middle Eastern countries and compare and contrast them with the published IIH literature from
Western countries. The incidence of IIH in several Middle East countries has been estimated at 2.02–2.2/100,000 in the general
population, which is higher than the Western rate. Obesity is a major risk factor globally and it is associated with an increased risk
of severe vision loss due to IIH. There has been an increase in obesity prevalence in the Middle East countries mainly affecting the
Gulf Council Countries (GCC), which parallels increased industrial development. This rise may be contributing to the increasing
incidence of IIH in these countries. Other risk factors may also be contributing to IIH in Middle East countries and the differences
and similarities to Western IIH merit further study.
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Idiopathic intracranial hypertension (IIH), also known as
primary pseudotumor cerebri, is a disorder of increased intra-
cranial pressure (ICP) with normal neuroimaging and CSF
composition and no underlying etiology. IIH typically affectsobese women of childbearing age but it may be seen in
patients of any age, in either gender, and without obesity.22
Other risk factors for secondary IIH are the use of exogenous
substances such as lithium, high doses of vitamin A, tetracy-
clines (especially minocycline), and corticosteroids (both with
steroid intake or more likely following steroid withdrawal).35e:
al.com
United
Idiopathic intracranial hypertension in the Middle East 27The diagnosis of IIH is one of exclusion and the modified
Dandy criteria are generally used to make the diagnosis
(Table 1).1,28 While once called ‘‘benign intracranial hyperten-
sion’’, the disorder is not necessarily a benign disorder as
some may suffer significant vision loss related to papilledema
and many may experience moderate to severe or intractable,
disabling headaches. In this review, we consider the epidemi-
ology and demographic features of IIH in the Middle East
countries and compare and contrast with the published
literature from Western countries.Epidemiology and obesity
Incidence
Many epidemiological studies have documented the asso-
ciation of IIH with female gender and obesity. In the United
States (US) the approximate annual incidence has been
reported to be 0.9–1/100,000 in the general population. The
incidence increases to 13–14.8/100,000 for women of ages
20–44 years who were 10% or more above ideal body weight
(IBW) and the incidence increases to 19.3/100,000 for women
in this age group when 20% or more above IBW.16 The inci-
dence varies from country to country probably related to the
prevalence of the obesity in the respective region. In the Shef-
field, UK study, the incidence was 1.56/100,000/year, 2.86/
100,000 in women, and 11.9/100,000 in obese women.18 The
reported annual incidence of IIH in several Middle East coun-
tries has been estimated at 2.02–2.2/100,000 in the general
population which is even higher than the Western statistics.
A study conducted in Libya demonstrated an annual incidence
of 2.2/100,000 in the general population, 4.3/100,000 in
women, 12/100,000 in women aged 15–44 years and 21.4/
100,000 in obese women.17 Another study performed in Oman
estimated an annual incidence of 2.18/100,000 in the general
population, 3.25/100,000 women in all age groups, and 4.14/
100,000 in the age group of 15–44 years.14 The reported
annual incidence of IIH in Israel was 2.02/100,000 in the general
population, 3.17/100,000 in women and 5.49/100,000 in
reproductive age group.20
The increased incidence of IIH in these countries could be
related to the globally increasing rates of obesity (Table 2).Obesity prevalence
Overweight and obesity are defined as abnormal or exces-
sive fat accumulation that presents a risk to health. Body
mass index (BMI), defined as a person’s weight in kilograms
divided by the square of height in meters (kg/m2), is a com-
monly used index to classify overweight and obesity in adults.
The World Health Organization (WHO) defines overweight as
a BMI of 25 or more and obesity as a BMI of 30 or more.40 InTable 1. Modified Dandy criteria.
Modified Dandy criteria
1. Symptoms, if present, and signs representing increased ICP or papillede
2. Documented elevated ICP measured in the lateral decubitus position
3. Normal CSF composition
4. Normal MRI or contrast-enhanced CT for typical patient and MRI and M
5. No other cause of increased ICP
ICP: intracranial pressure, MRI: magnetic resonance imaging, CT: computed tomography,its 2008 study of the global obesity epidemic, the WHO
estimated that more than 1.4 billion adults who were over-
weight and more than half a billion were obese. The preva-
lence of obesity has nearly doubled between 1980 and
2008. Globally over 40 million preschool children were over-
weight in 2008.40 The prevalence of obesity worldwide paral-
lels the increased industrial development across the world,
which in the GCC is related to the significant growth in
incomes and the resulting rapid urbanization and improved
living conditions.41 Table 3 provides the 2010 WHO statistics
for obesity in Western and Middle East countries. The rank
order in Middle East countries for obesity in women is Kuwait
55.2%, Egypt 48%, and United Arab Emirates (UAE) 42%. These
percentages are all higher rates than in any of the European
countries and about the same as the US (48.3%) and Mexico
(41%). Countries such as Bahrain (37.9%), Jordan (37.9%),
Saudi Arabia (36.4%), Tunisia (32.6%), Qatar (31.6%), Iran
(29.5%) and Lebanon (27.4%) also have higher obesity rates
in females than in European countries and Israel (25.9%).
The prevalence of overweight individuals is higher in men than
women in Western and European countries, but in the Middle
East countries, it is higher in women. Development, urbanization,
and improved living conditions in the Middle East countries have
led to greater consumption of higher calorie and potentially
unhealthy food intake, decreased physical activity and more
sedentary lifestyles, and an increase in the prevalence of obesity
in people of all age groups, especially women.41
Role of obesity on IIH
A recent case control study showed that higher levels of
weight gain and BMI were associated with a greater risk of
IIH.3 Obese and non-obese patients with recent moderate
weight gain (5–15% of their weight) also have a greater risk
of IIH. Recent weight gain in newly diagnosed IIH is also
common finding that has been reported by several other
studies.8,9,11 In one prospective study of 34 patients, 94%
of patients were overweight and 70.5% were obese.9
Another study of 50 women with IIH showed that 26 had
IIH recurrence.2 These patients had a greater BMI at the time
of recurrence compared to BMI at diagnosis. In contrast,
patients without recurrence demonstrated stable weights,
while patients with recurrence had a 6% weight gain,
suggesting that even moderate weight gain might be a risk
factor for recurrence.2
Similar to the Western literature, the publications on IIH
from GCC also show that obesity was the major risk factor
contributing to the cause of IIH. A retrospective study of 40
Omani patients diagnosed with IIH showed that 60% of
female patients were obese.14
Another study in Saudi Arabia included 99 patients who
were all Arab by ethnicity and ages between 12–48 years.
This study showed that 80% of patients were obese.21 Mezaalma
RV for all others
MRV: magnetic resonance venography, CSF: cerebrospinal fluid.
Table 2. Incidence of IIH in general population, women and obese women.
Country Incidence Incidence in
women
Incidence in childbearing
women
Incidence in obese women
US/Iowa 16 0.9/100,000 13/100,000 > 10% ideal body weight 19.3/100,000 20% ideal body weight
(childbearing)
US/Louisiana 16 1.07/100,000 14.85/100,000 > 10% ideal body weight
US/Minnesota 15 0.9/100,000 1.6/100,000 3.3/100,000 7.9/100,000
UK/Sheffield 18 1.56/100,000 2.86/100,000 11.9/100,000
Libya/Benghazi 17 2.2/100,000 4.3/100,000 12/100,000 21.4/100,000
Oman/South Sharaqiah 14 2.18/100,000 3.25/100,000 4.14/100,000
Israel 20 2.02/100,000 3.17/100,000 5.49/100,000
Table 3. Estimated overweight (BMIP 25 kg/m2) and obesity (BMIP 30 kg/m2) prevalence, males and females, aged 15+, WHO estimates for 2010.39
Region Country Overweight Male Overweight Female Obese Male Obese Female
Americas US 80.5 76.7 44.2 48.3
Canada 66.9 59.5 25.5 25.7
Mexico 73.7 73.0 30.1 41.0
Western Pacific Australia 75.7 66.5 28.4 29.1
New Zealand 73.9 74.2 28.9 39.9
Europe UK 67.8 63.8 23.7 26.3
Italy 55.0 40.0 14.4 13.7
Belgium 54.1 42.9 14.8 10.7
France 48.0 36.9 9.0 7.6
Germany 67.2 57.1 22.9 22.1
Middle East: GCC UAE 66.9 71.6 24.5 42.0
Kuwait 69.5 80.4 29.6 55.2
Bahrain 60.9 69.5 21.2 37.9
Qatar 59.5 65.9 18.7 31.6
Saudi Arabia 63.1 65.9 23 36.4
Oman 43.4 50.8 7.7 17.0
Middle East Jordan 57.5 65.4 19.6 37.9
Syria 50.4 59.6 12.4 24.6
Lebanon 51.7 56.7 14.9 27.4
Libya 50.8 59.8 12.7 24.9
Iraq 42.4 53.6 8.3 19.1
Iran 48.5 60.2 10 29.5
Israel 59.4 59.3 17.9 25.9
Tunisia 42.8 61.4 7.7 32.6
Yemen 24.6 32.2 2.0 6.2
28 S.J. Almarzouqi et al.and Sadaah et al. reported on 50 IIH patients from Dubai
(UAE) and again obesity was the most commonly associated
risk factor.10 Two studies conducted in Israel published in
2001 and 2014 by the same authors showed an increased
percentage of obesity of 57.2% and 83.4%, respectively, as
a major risk factor for IIH.19,20
The pathophysiological mechanism of obesity in IIH
remains unclear. Several hypotheses however include
metabolic and hormonal dysregulation.4 Obesity may raise
intra-abdominal pressure which may increase pleural
pressure and cardiac filling pressure leading to increased
intracranial venous pressure and elevated ICP.36 Despite
the major role of obesity in causing IIH, rarely non-obese
patients of both genders also may develop the syndrome of
IIH. A recent study showed that 4% of patients of both genders
with IIH at the time of diagnosis were of normal weight.5
IIH is uncommon in children. Interestingly, there is less pre-
dilection for obese girls in prepubertal children; however, the
rate of obesity and gender predilection in post-pubertal chil-
dren is similar to that in adult IIH population.7 In a retrospec-
tive study of 12 children with IIH, obesity was noted in 75%
of patients and 100% in children above 12 years.13 Similarly,
a retrospective study done in Israel reported no association
between obesity and IIH in prepubertal children but their asso-ciation more pronounced in the pubertal age group which is
similar to the adult population with IIH.23 In this study, 59%
of involved children with IIH were overweight or obese. This
study also showed the male predominance in the prepubertal
group and female predominance in the pubertal group. While
in another study conducted in Oman, thirteen patients of 40
were children below the age of 15, all of them were non
obese.14 This finding needs further evaluation to explore any
other unidentified risk factor contributed to high incidence
of IIH in Omani children. Being overweight or obese has an
important role in the recurrence rate of IIH in the pediatric
age group. A cohort study of 43 children with IIH showed that
the risk of IIH recurrence was found five fold in overweight or
obese children.12 There was no available published literature
in GCC or other Middle East countries about IIH in the pediat-
ric age group and its associated risk factors.
IIH in men is rare. Only 9% of IIH patients in a recent large
series were male.6
Affected men have a similar BMI when compared with
affected women, but are, on average, about a decade older
than women at the time of presentation.6 In contrast, obesity
is not as significant of a risk factor in men as it has been
reported by available published studies in GCC but the study
numbers are limited.10,14
Idiopathic intracranial hypertension in the Middle East 29Clinical presentation
Patients with IIH typically present with symptoms and
signs of elevated ICP. Headache is the most common pre-
senting symptom reported by IIH patients, occurring in more
than 90% of cases in most studies.15,24,25 Some patients have
accompanying neck stiffness or retrobulbar pain, the latter
sometimes exacerbated by eye movements. Similar findings
were reported by studies performed in GCC where 100%
of involved patients in Oman, 97% in Saudi Arabia and 98%
in Dubai (UAE) presented with headache.10,14,21
Many IIH patients are awakened by headache and they
often suffer from daily headache.25 Other symptoms may
include transient visual obscurations (TVOs), blurred vision,
recognition of enlarged blind spot or other visual field loss,
diplopia (due to non-localizing sixth nerve palsy), and
pulse-synchronous tinnitus (PST). Vision loss in IIH is usually
due to papilledema and secondary optic neuropathy. Almost
all patients with IIH have papilledema (although it may be
absent). When present the papilledema is usually bilateral
and symmetric, but can be slightly asymmetric or unilateral
in about 10% of patients.26 Visual acuity typically remains
normal in the early stages of papilledema. The visual field
defects are typically nerve fiber in character (or an enlarged
blind spot). This peripheral vision loss is typically insidious
and many patients are unaware of minor deficits because
central vision is usually spared until late. An uncommon, but
well-recognized fulminant presentation can occur, in which
patients develop acute and severe vision loss over days.38
Focal neurological deficits other than vision loss and sixth
nerve palsy are not associated with IIH.Diagnostic evaluation, clinical management and
treatment
The initial evaluation of a patient with suspected IIH
should consist of complete ophthalmic and neurologic
examinations, including formal visual field testing. Patients
with IIH should undergo magnetic resonance imaging (MRI)
with and without contrast, which is preferred over computed
tomography (CT) scanning with contrast, to rule out tumor,
hydrocephalus, and meningeal lesion. Magnetic resonance
venography (MRV) should be considered to assess for venous
sinus occlusion especially in atypical IIH (e.g., men, thin
patients, elderly).28 Common characteristic MRI findings in
IIH include an empty sella, flattening of the posterior globe,
and enlarged optic nerve sheaths. Stenosis or narrowing of
the distal transverse sinus-sigmoid sinus junction is common
in IIH and it remains controversial as to whether this is
contributory, coincidental with, or causal of the increased
ICP in IIH. If neuroimaging is normal, a lumbar puncture (LP)
is necessary to document elevated opening pressure and to
rule out CSF infectious, neoplastic, or inflammatory causes.
Assessment of optic nerve function (e.g., testing of visual
acuity, color vision, pupillary reactions, formal visual fields)
and funduscopy should be done at initial and follow up visits.
Treatment of IIH patients depends on their symptoms and
vision status.
Asymptomatic patients with normal vision and minimal
papilledema can be monitored frequently for the development
of symptoms or vision loss. If headache is controlled with
analgesic and no vision loss, patients may be managedconservatively. The treatment of IIH patients can be divided
into medical treatment and surgical treatment. The main stay
of medical treatment is weight loss. All overweight and obese
patients are strongly encouraged to lose weight. Improvement
in IIH has been reported following a weight reduction diet
and gastric bypass surgery.42,43 IIH patients with mild to
moderate vision loss typically require medical therapy.
Acetazolamide, a carbonic anhydrase inhibitor, is the first-line
medication in these instances. The recently completed IIH
treatment trial (a major recent multi-center, randomized,
double-blinded, placebo-controlled study) showed that
weight reduction coupled with acetazolamide was a safe
and effective treatment for IIH. The use of acetazolamide
with a low-sodium weight reduction diet, compared with
diet alone, resulted in modest improvement in the visual field
function in the IIHTT.44
Patients with intractable headache, severe vision loss at
presentation or progressive vision loss despite maximum
medical management, may require surgical intervention.
The primary surgical options are optic nerve sheath fenestra-
tion (ONSF) or a CSF diversion procedure (e.g., lumbo-
peritoneal shunt (LPS) or ventriculo-peritoneal shunt (VPS)).
No significant differences were found in the evaluation,
assessment, management and treatment of IIH patients in
studies performed in GCC versus the Western literature but
the effect of weight reduction alone was not studied
prospectively in the GCC studies.10,21 In contrast, 35 of 40
patients in Oman study underwent CT scan alone and 5
patients had MRI and none had an MRV.14 This may contribute
partly to high incidence of IIH in this study as CT scan is not
considered sufficient to make the diagnosis of IIH in the
Western literature.Outcome
Vision loss is the main long-term complication of IIH.
Patients with mild to moderate vision loss tend to recover
vision following maximum medical therapy. Papilledema in
treated cases usually resolves completely over weeks or
months but many patients are left with some residual disc
elevation or mild gliosis or optic atrophy. Patients with severe
vision loss at presentation or who fail maximum medical therapy
may require surgery and these patients often have some
potential for residual visual acuity and/or visual field defects.
Rarely, cases act in a malignant fashion (i.e., fulminant IIH)
and seem recalcitrant to medical and surgical therapy and
result in severe secondary optic atrophy.
In a study of 57 patients, 24.6% of patients had severe
visual impairment about 5–41 years after the initial diagno-
sis.30 Visual impairment was also reported in 13% of patients’
eyes at initial visit with no significant changes at final visit and
4% of patients became blind in both eyes in one study.24
Comparing these findings with findings in the available
Middle East studies of IIH, the percentage of final visual
impairment was similar. One third of patients involved in the
retrospective study in Saudi Arabia had decreased visual acu-
ity, 19.2% were visually impaired, and 2% were blind at initial
presentation.21 Following surgical or medical therapy 87% of
all patients had excellent outcome. At late assessment 13.1%
were visually impaired and 2% were blind. 20% of patients
in study performed in Libya had moderate to severe vision
loss which did not correlate with any specific risk factor.17
30 S.J. Almarzouqi et al.These findings suggest that there is no difference in the visual
outcomes in Arab populations with IIH. In contrast, one
study from Dubai (UAE) reported an excellent outcome in
95.2%.10 There are some demographic factors affecting the
prognosis. Large Western studies suggest that men and black
(African–American) patients have a worse visual prognosis
than women and non-black patients, respectively, with IIH.
Although race does not seem to directly influence the
incidence of IIH, race may be an important determining factor
of a patients’ visual prognosis. IIH in some studies was worse
in black patients compared with whites living in the US,33 and
was worse in white US IIH patients compared with white
French IIH patients.34 There was no similar racial studies done
for IIH in the Middle East, and the demographics of race
differ significantly in the GCC compared with the US. The
demographics of the GCC, however, are rapidly evolving
with expatriates from the Western world (Europe, North
America, Australia/New Zealand), Asia (China, India, Pakistan,
Bangladesh, and the Philippines), and Africa.
Although men develop IIH less frequently than women,
their visual prognosis may be worse, perhaps because
they have less prominent headaches to alert them to the
problem.6 Additionally, in a more recent study, increasing
degrees of obesity were associated with an increased risk
of severe vision loss, suggesting that very obese IIH patients
should be closely monitored for progression of visual field
loss.27 Other underlying conditions which may predispose
to a worse visual outcome include older age, high myopia,
anemia, hypertension and uremia. The role of these specific
risk factors has not been studied in detail in the GCC and
other Middle East countries.
Recurrence can occur, and rarely some patients with IIH
develop a chronic form requiring years of medical treatment.
Kesler et al. reported almost 40% recurrence rate of IIH over
a mean observation period of 6.2 years.31 In a recent retro-
spective study of 20 patients who were followed up for over
10 years, three patients had recurrence about 12–78 months
after the initial resolution. A further six patients experienced
delayed worsening about 28–135 months after an initial sta-
ble course.32 Eight of 30 Omani patients who were medically
treated had recurrence after one year and six of all patients
experienced chronic course.14 Since delayed worsening and
recurrence occur, patients with IIH should be kept under
long-term follow up, especially patients having risk factors
of worse visual prognosis.Conclusion
IIH represents an increasing burden to public health as
well as clinical practice especially in countries experiencing
epidemic obesity, such as the GCC. For the most part, the
available evidence suggests that the clinical findings, evalua-
tion, management, treatment, and prognosis of IIH in the
GCC are similar to the Western presentation of IIH. The etiol-
ogy of increased ICP in IIH is unclear and remains a topic of
much interest and continued research. The incidence in the
general population of the Middle East countries is higher
than in Western countries, and it is higher in obese females.
Obesity is the major risk factor in occurring and recurrence
of IIH and is associated with an increased risk of severe vision
loss.37 Identification of patients at high risk for irreversible
vision loss, such as black (African–American) patients, men,and patients with fulminant IIH may help to determine the
best risk stratified management approaches and refine indi-
vidualized treatment and follow-up strategies.29 Many ques-
tions remain unanswered about IIH and other risk factors in
the Middle East population due to lack of controlled studies
and the changing demographics in the GCC. Further studies
are necessary to determine if IIH in the GCC should be
treated the same or differently than in the western literature.Conflict of interest
The authors declared that there is no conflict of interest.
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